A new report titled "CNS Therapeutics: A Global Strategic Business Report", has been released by Global Industry Analysts, Inc. The report provides an extensive review of market trends, drivers, players and competition. The report also offers profiles of leading players and presents recent developments, mergers, acquisitions, as well as other strategic industry activities. The study analyzes six major product segments including Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants and others. Detailed analysis is provided for major geographic markets including United States, Canada, Japan, France, Germany, the UK, Italy, Spain, Asia-Pacific, Latin America and rest of world.

CNS disorders represented 11% of global disorders in 2002 and are expected to account for over 14% by 2020, spurred by ageing population and changing life styles. Global market for CNS therapeutics is likely to register growth of nearly 7.5%. Anti-Psychotics drug sales (http://www.strategyr.com/MCP-1835.asp) account for nearly 25% of the US$43 billion CNS therapeutics market in the United States.

Anti-Alzheimer's drugs market (http://www.strategyr.com/MCP-1835.asp) is projected to be the fastest growing segment of Asia-Pacific CNS therapeutics market. European CNS Therapeutics market is expected to be worth US$30 billion by 2010. Increase in diagnosis of multiple sclerosis and Alzheimer's in the US is also influencing demand for CNS prescriptions. Nearly 1.5 billion people, including 100 million Americans are afflicted with some form of CNS disorder.

While the available therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression, and hence spur market growth. Continuing switch over of patients from typical or traditional anti-psychotics to expensive and safer atypical anti-psychotics drugs, such as Zyprexa, Risperdal and Geodon is driving the market forward. Global market for anti-depressants, a dominant product category of CNS therapeutics is on a decline, succumbed by increasing generic competition, loss of patent protection of key drugs, and increased risk of suicidal tendencies among adolescents.

Major players in the CNS Therapeutics market include Abbott Laboratories, Organon N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Eli Lilly and Co, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Johnson & Johnson, Merck & Co, Novartis AG, Sandoz International, Otsuka Pharmaceutical Co, Pfizer, Inc., Sanofi-Aventis, Schwarz Pharma, Takeda Pharmaceutical Co, Teva Pharmaceutical Industries Ltd, UCB S.A., Wyeth.

For more details about this research report, please visit www.strategyr.com/MCP-1835.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) (http://www.strategyr.com) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc. Telephone 408-528-9966 Fax 408-528-9977

Web Site www.StrategyR.com